Nasdaq: AZTAAzenta, Inc.

    Azenta Q4 2026 Results: Net Income $6.79 Million on Revenue of $167 Million

    • US stocks
    • Earnings
    • Health Care
    A gloved hand holding a petri dish in a laboratory
    Drew Hays (Unsplash), via Wikimedia Commons (CC0). Illustrative image.

    Azenta (Nasdaq: AZTA) reported GAAP revenue of $167.1 million and GAAP net income of $6.8 million for the fiscal 2026 fourth quarter, the quarter ended 30 Sep 2026, it said on 10 Nov 2026 in its earnings release. GAAP diluted EPS was $0.16, and adjusted diluted EPS, a company-defined measure, was $0.28.

    Key highlights

    • Revenue (GAAP): $167.1 million, up 5.0% YoY
    • Operating income (GAAP): $2.5 million, up 31.8% YoY
    • Net income (GAAP): $6.8 million, down 86.7% YoY
    • Diluted EPS (GAAP): $0.16, down 85.6% YoY
    • Adjusted diluted EPS (company-defined): $0.28

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ4 2026Q4 2025YoY
    Revenue167.1159.2+5.0%
    2.51.9+31.8%
    6.850.9-86.7%
    Diluted EPS ($)0.161.11-85.6%

    Figures are in $ million except EPS; YoY compares with Q4 2025. Q4 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are the release's own comparatives, not cross-checked against SEC XBRL data. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table compares GAAP results for the quarter ended 30 Sep 2026 with the same quarter a year earlier. Revenue rose 5.0% to $167.1 million, and operating income rose 31.8% to $2.5 million, a 1.5% margin against 1.2% a year earlier. GAAP net income fell 86.7% to $6.8 million from $50.9 million. The release says the year-ago quarter included a one-time $45.6 million tax benefit, which the company excludes from its adjusted figures.

    Adjusted figures exclude amortization, restructuring and deal costs

    Adjusted measures are the company's own non-GAAP figures. Adjusted diluted EPS was $0.28 against $0.21 a year earlier. The company excludes items such as amortization of intangible assets, restructuring charges, transformation costs and merger and acquisition costs, and it says adjusted diluted EPS does not exclude stock-based compensation. Adjusted EBITDA was $19.4 million, an 11.6% margin that the company said was 140 basis points lower year over year.

    Sample Management Solutions revenue was $94.0 million, up 9%, with organic growth of 4%, which the company said came mainly from higher sample repository services and consumables and instruments. Multiomics revenue was $73.0 million, flat, with organic revenue down 1%.

    Fiscal 2026 included a $149.0 million goodwill impairment

    Fiscal 2026 revenue was $622.0 million, up 5%, and the operating loss was $174.7 million. That loss included a non-cash goodwill impairment charge of $149.0 million, recognized in the second quarter. The release says the charge followed a quantitative goodwill analysis as of 31 Mar 2026.

    Fiscal 2027 outlook and the Elegen and SynPlexity deals

    The company expects fiscal 2027 reported revenue from continuing operations of $648 million to $660 million, organic growth of 3% to 5%, and adjusted EBITDA margin expansion of 200 to 250 basis points. On 28 Oct 2026 it entered Elegen agreements with fixed license payments of $23.0 million, and it acquired SynPlexity for a $15.0 million base price in cash. The company said the high end of the revenue outlook includes potential contributions from both.

    Inference

    Weighted average diluted shares were 43,465 thousand in the quarter, against 45,994 thousand a year earlier, and 41,757,019 shares were outstanding at 30 Sep 2026, against 45,858,979 at 30 Sep 2025. In fiscal 2026 the company repurchased 4.4 million shares for $118.2 million, excluding fees, commissions and excise tax, leaving $131.8 million under its 2025 program. Free cash flow, on a total company basis, was $12 million in the quarter and $27 million for the year.

    The release does not give a dividend, a fiscal 2027 GAAP EPS outlook or a name for a permanent chief executive. The fiscal 2027 outlook covers the year ending 30 Sep 2027.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts